Breaking News, Collaborations & Alliances

AGC Biologics Inks Exosome Pact with Jikei U in Japan for IPF Project

AGC will assume technology transfer and feasibility study for drug product for the treatment of Idiopathic pulmonary fibrosis at its Cell & Gene CoE in Milan.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has signed a service agreement with The Jikei University in Japan. AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at AGC’s center of Cell and Gene Excellence in Milan.   In the feasibility study, the Milan site will focus on identifying proof of concept and viability for developing a prototype f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters